LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Haematologica

Topics

Medicine

Cancer Oncology

Immunology

Hematology

Myeloid

Show all topics

DOI

10.3324/haematol.2024.285099

License

CC-BY-NC

Other Formats

PDF